Compare Fox Corp Class A (FOXA) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class A vs IDEXX Laboratories, Inc. — how do they compare? Fox Corp Class A trades at $62.41 (market cap $25.36B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Fox Corp Class A pays a 0.91% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class A for 34 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| FOXA | IDXX | |
|---|---|---|
Market Cap | $25.36B | $40.43B |
Volume | 2,566,954 | 692,164 |
Sector | Media | Health |
52-Week High | $76.11 | $766.68 |
52-Week Low | $48.79 | $504.70 |
Typical Hold Time | 34 Days | 46 Days |
Enterprise Value | $28.72B | $41.32B |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fox Corporation (FOXA) trades at $63.57, up 1.39% today, with a bullish technical signal and strong fundamental performance. Recent quarters show consistent earnings beats, with Q2 2026 EPS of $1.79 exceeding the $1.44 estimate. The company's 2025 revenue grew to $16.3 billion, with a net income margin of 13.88%, while analyst consensus is bullish with a $72 price target. Key developments include the pending $22 billion Roku acquisition, currently under DOJ review, and insider buying by CEO Lachlan Murdoch.
The outlook for FOXA is positive, supported by earnings momentum, reasonable valuation (P/E 16.55), and strategic acquisitions. However, risks include regulatory scrutiny of the Roku deal and potential integration challenges. The stock offers upside to the consensus target but faces headline volatility from merger progress.
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
